Patents by Inventor Dan L. Longo
Dan L. Longo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150309026Abstract: The invention relates to methods and compositions for identifying subjects having, or predisposed to having, a neoplastic or cell proliferation or neoplastic disorder. The methods are applicable to any type of tissue sample and can be conducted on otherwise normal tissue.Type: ApplicationFiled: July 14, 2015Publication date: October 29, 2015Inventors: Andrew P. Feinberg, Christine A. Iacobuzio-Donahue, Dan L. Longo, Minoru Ko
-
Patent number: 9086403Abstract: The invention relates to methods and compositions for identifying subjects having, or predisposed to having, a neoplastic or cell proliferation or neoplastic disorder. The methods are applicable to any type of tissue sample and can be conducted on otherwise normal tissue.Type: GrantFiled: June 3, 2005Date of Patent: July 21, 2015Assignees: The Johns Hopkins University, National Institutes of HealthInventors: Andrew P. Feinberg, Christine A. Iacobuzio-Donahue, Dan L. Longo, Minoru Ko
-
Publication number: 20110014204Abstract: The present invention relates to targets of loss of imprinting (LOI) affected IGF2 gene products in pre-malignant tissues, where methods of inhibiting those targets, including IGFR1, are disclosed to prevent tumor development in subjects at risk for developing colorectal cancer (CRC). The present invention also relates to methods of identifying increased risk in developing CRC in a subject, including methods of assessing the efficacy of a chemotherapeutic regimen. Further, the present invention relates to methods for identifying anti-neoplastic agents.Type: ApplicationFiled: December 7, 2007Publication date: January 20, 2011Inventors: Andrew P. Feinberg, Andre Levchenko, Dan L. Longo, Minoru S.H. Ko
-
Patent number: 5965366Abstract: Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM).Type: GrantFiled: June 23, 1997Date of Patent: October 12, 1999Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, Biormia USA Inc.Inventors: Augusto C. Ochoa, Howard A. Young, Dan L. Longo, Paritosh Ghosh
-
Patent number: 5889143Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.Type: GrantFiled: September 16, 1996Date of Patent: March 30, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Augusto C. Ochoa, Dan L. Longo, Paritosh Ghosh, Howard A. Young
-
Patent number: 5861158Abstract: This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. Also provided is a composition comprising purified hematopoietic cells primed to produce an immunological response to foreign tumor specific antigen. Also provided is a method of treating a tumor by the transplantation of hematopoietic cells from a donor to a recipient to treat the tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's tumor, and transplanting the donor's immunized hematopoietic cells to the recipient.Type: GrantFiled: November 17, 1993Date of Patent: January 19, 1999Assignee: The United States of America as represented by the Deptartment of Health and Human ServicesInventors: Larry W. Kwak, Dan L. Longo
-
Patent number: 5725855Abstract: The present invention provides a method for enhancing the immunotherapeutic activity, e.g., antitumor activity, of immune cells by depleting immune cells of a cell subset that down-regulates the immune response, such as either CD4.sup.+ or CD8.sup.+ lymphocytes. The remaining depleted immune cell population or the separated immune cell subsets then are cultured in the presence of an antibody to a lymphocyte surface receptor, preferably an anti-CD3 monoclonal antibody (MoAb), optionally in the presence of a relatively minor amount of interleukin-2 (IL-2). These stimulated cells then are optionally additionally cultured in the presence of IL-2 without an antibody to a lymphocyte surface receptor. The present invention also provides a method of treating a mammal having tumors or immunizing a mammal against tumors by administering the stimulated depleted immune cell population or a stimulated immune cell subset to a mammal, advantageously together with an immunosuppressant, and with liposomal IL-2.Type: GrantFiled: March 22, 1994Date of Patent: March 10, 1998Assignees: The United States of America as represented by the Department of Health and Human Services, Regents of the Univ. of MinnesotaInventors: Augusto Carlos Ochoa, Mark L. Saxton, Dan L. Longo
-
Patent number: 5674492Abstract: There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40, in individuals at risk for such disease.Type: GrantFiled: December 21, 1994Date of Patent: October 7, 1997Assignees: Immunex Corporation, The United States of America as represented by the Department of Health and Human ServicesInventors: Richard J. Armitage, William C. Fanslow, III, Dan L. Longo, William J. Murphy
-
Patent number: 5658744Abstract: Methods of identifying a patient having an altered immune status involve determining an immune status index for the patient and comparing it to the immune status index in healthy individuals. In general, an immune status index is the ratio of the amount of a protein that varies significantly in a patient with an altered immune status to the amount of another protein that is substantially invariant in both healthy and immune-altered individuals. Variable proteins can be TCR subunit proteins, T lymphocyte signal transduction pathway proteins, polynucleotide binding proteins or biological response modifiers (BRM).Type: GrantFiled: July 22, 1994Date of Patent: August 19, 1997Assignees: The United States of America as represented by the Department of Health and Human Services, Biomira USA Inc.Inventors: Augusto C. Ochoa, Howard A. Young, Dan L. Longo, Paritosh Ghosh, Richard Robb, Mary Neville
-
Patent number: 5583002Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels and T-lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, or a protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.Type: GrantFiled: December 11, 1992Date of Patent: December 10, 1996Assignees: Regents of the University of Minnesota, The United States of America as represented by the Department of Health and Human ServicesInventors: Augusto C. Ochoa, Hiromoto Mizuguchi, John J. O'Shea, Dan L. Longo, Cynthia M. Loeffler
-
Patent number: 5556763Abstract: A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-.kappa.B/rel family and comparing the level and pattern to that found in non-immunosuppressed individuals. The method is useful to identify patients having T lymphocytes capable of activation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppressive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.Type: GrantFiled: March 17, 1993Date of Patent: September 17, 1996Assignee: United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Augusto C. Ochoa, Dan L. Longo, Paritosh Ghosh, Howard A. Young
-
Patent number: 5316763Abstract: The present invention is directed to a method of increasing the in vivo immune response of lymphocytes by stimulating the lymphocytes in vitro in the presence of an anti-CD3 monoclonal antibody for less than about 24 hours to form stimulated lymphocytes; infusing the stimulated lymphocytes into a tumor-bearing mammal; and administering IL-2 to the mammal. As a result of this method, the anti-CD3 stimulated lymphocytes display enhanced immunotherapeutic, e.g., cytotoxicity or lymphokine production, in vivo as represented by a decrease in the number of tumors by at least about 20%.Type: GrantFiled: July 10, 1992Date of Patent: May 31, 1994Assignees: The United States of America as represented by the Department of Health and Human Services, Regents of the University of MinnesotaInventors: Augusto C. Ochoa, Cynthia Loeffler, Walter Urba, Dan L. Longo
-
Patent number: 5296353Abstract: A method of determining the level of immunosuppression in a mammal involves determining the level of expression of at least one selected TCR subunit protein, or protein in the T lymphocyte signal transduction pathway, and comparing the level to that found in healthy individuals. The method is useful to identify patients having T lymphocytes capable of activation for autologous adoptive immunotherapy and for identifying agents which cause or reverse immunosuppression.Type: GrantFiled: April 6, 1992Date of Patent: March 22, 1994Assignees: The United States of America as represented by the Department of Health and Human Services, Regents of the University of MinnesotaInventors: Augusto C. Ochoa, Hiromoto Mizoguchi, John J. O'Shea, Dan L. Longo, Cynthia M. Loeffler